Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 169-177

  Cicora, F ^a,c,d   Roberti, J ^c   Vasquez, D ^d   Guerrieri, D ^b,e   Lausada, N ^a   Cicora, P ^b   Palti, G ^d   Chuluyan, E ^e   Gonzalez, P ^f   Stringa, P ^a   Raimondi, C ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Foundation for the Research   (Argentina)

^c UNIVERSIDAD DE BELGRANO   (Argentina)

^d HOSPITAL ALEMÁN   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f Universidad Provincial del Sudoeste   (Argentina)

Author keywords

Acute tubular necrosis; Apoptosis; Donor preconditioning; Rapamycin; Tacrolimus

Indexed keywords

CREATININE; INTERLEUKIN 6; PROTEIN BCL 2; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; EXPLORATORY RESEARCH; HISTOPATHOLOGY; ISCHEMIA; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL; WISTAR RAT;

ANIMALS; APOPTOSIS; BLOOD UREA NITROGEN; COMPLEMENT C3; CREATININE; CYTOKINES; DRUG EVALUATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPERFUSION INJURY; SIROLIMUS; TACROLIMUS;

EID: 82655181541     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04487.x     Document Type: Article

References (54)

1. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64:945-7.
2. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155:1831-40.
3. Jang HR, Ko GJ, Wasowska BA, Rabb H. The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 2009; 87:859-64.
4. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2007; 123:7-13.
5. Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162:196-203.
6. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20:217-26.
7. Genesca M, Sola A, Hotter G. Actin cytoskeleton derangement induces apoptosis in renal ischemia/reperfusion. Apoptosis 2006; 11:563-71.
8. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172:3869-75.
9. Zhou W, Farrar CA, Abe K etal. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105:1363-71.
10. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97:2259-67.
11. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6:652-8.
12. Kuecuek O, Mantouvalou L, Klemz R etal. Significant reduction of proinflammatory cytokines by treatment of the brain-dead donor. Transplant Proc 2005; 37:387-8.
13. Kotsch K, Ulrich F, Reutzel-Selke A etal. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008; 248:1042-50.
14. Gottmann U, Brinkkoetter PT, Hoeger S etal. Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition. Transplantation 2007; 84:755-62.
15. Goncalves GM, Cenedeze MA, Feitoza CQ etal. The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury. Transplant Proc 2007; 39:417-20.
16. Yang CW, Ahn HJ, Han HJ etal. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. Transplantation 2001; 72:1753-9.
17. Cicora F, Lausada N, Vasquez DN etal. Protective effect of immunosuppressive treatment before orthotopic kidney autotransplantation. Transplant Immunol 2011; 24:107-12.
18. Coombes JD, Mreich E, Liddle C, Rangan GK. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005; 68:2599-607.
19. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50:1110-17.
20. Lieberthal W, Fuhro R, Andry CC etal. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281:F693-706.
21. Puglisi RN, Strande L, Santos M, Schulte G, Hewitt CW, Whalen TV. Beneficial effects of cyclosporine and rapamycin in small bowel ischemic injury. J Surg Res 1996; 65:115-18.
22. Inman SR, Davis NA, Olson KM, Lukaszek VA, McKinley MR, Seminerio JL. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury. Urology 2003; 62:750-4.
23. Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM. Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transplant Int 2006; 19:834-9.
24. Khan S, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RC. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 2006; 41:256-64.
25. Frantz B, Nordby EC, Bren G etal. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J 1994; 13:861-70.
26. Sakr MF, Hassanein TI, Zetti GM, Van Thiel DH. FK 506 ameliorates the hepatic injury associated with ischemia. Life Sci 1990; 47:687-91.
27. Sakr M, Zetti G, McClain C etal. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation 1992; 53:987-91.
28. Kouwenhoven EA, de Bruin RW, Bajema IM, Marquet RL, Ijzermans JN. Cold ischemia augments allogeneic-mediated injury in rat kidney allografts. Kidney Int 2001; 59:1142-8.
29. Kaminska D, Tyran B, Mazanowska O etal. Cytokine gene expression in kidney allograft donor biopsies after cold ischemia and reperfusion using in situ RT-PCR analysis. Transplant Proc 2003; 35:2155-6.
30. de Vries DK, Lindeman JH, Ringers J, Reinders ME, Rabelink TJ, Schaapherder AF. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant 2011; 11:1064-70.
31. Guan X, Dei-Anane G, Liang R etal. Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J Surg Res 2008; 146:127-34.
32. Huang H, He Z, Roberts LJ 2nd, Salahudeen AK. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. Am J Transplant 2003; 3:1531-7.
33. Wells WA, Rainer RO, Memoli VA. Equipment, standardization, and applications of image processing. Am J Clin Pathol 1993; 99:48-56.
34. Shihab FS, Bennett WM, Andoh TF. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. Transplantation 2009; 87:326-9.
35. Smith KD, Wrenshall LE, Nicosia RF etal. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14:1037-45.
36. McTaggart RA, Gottlieb D, Brooks J etal. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3:416-23.
37. Novick AC, Hwei HH, Steinmuller D etal. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 1986; 42:154-8.
38. Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. Transplantation 2004; 78:338-44.
39. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10:330-6.
40. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 2006; 82:17-22.
41. Podder H, Stepkowski SM, Napoli K, Kahan BD. Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction. Transplant Proc 2001; 33:2-29.
42. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003; 76:1594-9.
43. Sun Q, Liu Q, Zheng Y, Cao X. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 2008; 45:2929-36.
44. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007; 7:1819-24.
45. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168:5817-23.
46. Misseri R, Meldrum DR, Dinarello CA etal. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 2005; 288:F406-11.
47. Zheng X, Feng B, Chen G etal. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006; 6:2099-108.
48. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 2006; 6:308-17.
49. Thurman JM, Ljubanovic D, Royer PA etal. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116:357-68.
50. Sacks SH, Zhou W. Locally produced complement and its role in renal allograft rejection. Am J Transplant 2003; 3:927-32.
51. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997; 107:1-7.
52. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004; 165:1677-88.
53. David S, Biancone L, Caserta C, Bussolati B, Cambi V, Camussi G. Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant 1997; 12:51-6.
54. Pratschke J, Wilhelm MJ, Kusaka M etal. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg 2000; 232:263-71.